Peritoneal cancer refers to the cancer that begins in the peritoneum, the thin lining surrounding many organs in the abdominal and pelvic regions. The peritoneum lines the walls of the abdomen and covers organs like the intestines, stomach, and liver. Peritoneal cancer arises from metastatic tumors that have spread from organs such as the appendix, colon, ovaries, stomach, or other sites.
The Global Peritoneal Cancer Market is estimated to be valued at USD 5.9 Bn in 2024 and is expected to reach USD 15.9 Bn by 2031, growing at a compound annual growth rate (CAGR) of 17.9% from 2024 to 2031.
Peritoneal Cancer Market is a rare disorder and its early diagnosis remains challenging. However, advancements in diagnostic tools are enabling improved detection of peritoneal tumors. The rising prevalence of cancers spreading to the peritoneum and growing awareness about early diagnosis are some of the primary factors driving demand for peritoneal cancer treatment drugs and devices.
Key Takeaways
Key players operating in the peritoneal cancer market are F Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly and Company, Bristol-Myers Squibb Company and Astellas Pharma Inc.
The growing incidence of various cancers that commonly metastasize to the peritoneum such as ovarian cancer is a key factor expected to fuel demand for peritoneal cancer diagnosis and treatment over the next decade.
Technological advancements in diagnostic modalities such as biomarker analysis and imaging techniques have enabled earlier and more accurate detection of peritoneal carcinomatosis, thereby supporting timely intervention.
Market Trends
Increasing Adoption of Targeted Drug Therapies: Targeted drugs that block the growth and spread of cancer by interfering with specific molecules involved in tumor growth and progression are rapidly replacing conventional chemotherapies for peritoneal cancer treatment. Drugs such as bevacizumab, ramucirumab and regorafenib exhibit high efficacy with lesser side effects.
Rising Popularity of Minimal Invasive Surgery: Minimal invasive surgeries like laparoscopy are increasingly being used for optimal cytoreductive surgery in peritoneal carcinomatosis patients. This leads to reduced post-operative complications, shorter recovery times, and improved quality of life for patients.
Market Opportunities
Synergistic Potential of Immuno-oncology Drugs: Emerging clinical evidence highlights the synergistic anti-tumor activity of immunotherapy drugs like nivolumab and ipilimumab when used in combination with chemotherapy for peritoneal surface malignancies. Such opportunities will augment treatment outcomes.
Personalized Medicine Approach: Growing focus on tailoring treatment based on a patient's genetic profile and tumor characteristics through genomic and proteomic analysis is likely to transform peritoneal cancer management in the coming years.
Peritoneal Cancer Market: Impact of COVID-19
The COVID-19 pandemic has significantly impacted the peritoneal cancer market growth globally. During the initial phase of lockdowns imposed by various countries, numbers of cancer screenings and diagnosis considerably declined. Constraints in conducting non-urgent surgeries also affected the market. However, with relaxation in lockdown measures, the market is expected to gradually recover over the coming years. Telehealth and virtual consultations gained prominence during this period, helping in continuity of care to some extent.
Still, the full recovery may take longer considering economic stress faced by many. Ensuring safety of immunosuppressed cancer patients remain a key concern as well. Post COVID, focus on digitalizing healthcare systems, remote monitoring tools and strengthening support for cancer patients will be important for sustainable market growth. Investments in immunotherapy and targeted drug development also picking pace that shall drive the market in medium to long run. Asia Pacific currently holds the major share of global peritoneal cancer market value owing to large patient base and rising healthcare expenditures in countries like China and India. Europe is another prominent regional market supported by higher acceptability of advanced treatments. Meanwhile, North America remains the fastest growing regional market attributed to ongoing RD activities and new approvals.
One of the fastest growing regional markets for peritoneal cancer is Latin America. Economic development, expanding medical infrastructure and initiatives to strengthen cancer care are supporting growth. Countries like Brazil, Mexico are witnessing rising incidence of peritoneal cancers owing to lifestyle changes and aging population. Growing awareness about early diagnosis and new treatment options available is positively impacting the market. However, affordability remains a challenge for many patients still. With projected increase in healthcare spending over the coming years across Latin American countries, the peritoneal cancer market in the region is anticipated to witness double digit growth rate during the forecast period.
Get more insights on : Peritoneal Cancer Market
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
